Thanks to recommendations made by organisations including CPIC, the FDA and European Medical Agency, as well as the availability of affordable commercial DPYD genotyping assays, severe adverse toxicity events and deaths due to 5-FU therapy are entirely preventable.
In May 2022, Oregon Health & Science University promised to change an aspect of its cancer treatment and pay out $1 million to settle a lawsuit claiming the university’s negligence killed a cancer patient, David McIntyre.
The university did not disclose the risk of the genetic condition to Mr. McIntyre that led to his severe adverse reaction to his chemotherapy, nor that it can be tested for.
Although testing for the genetic condition isn’t standard practice in the USA, OHSU will now include education [on DPD Deficiency] in its Oncology Fellowship program.
As part of the settlement, the university’s oncologists will now be required to tell patients about [DPD Deficiency] before initiating the chemotherapy drug capecitabine.
Read the OHSU article here: https://hubs.la/Q025rLnX0
Furthermore, “Zero severe toxicity events [have been] reported since the programme was rolled out. A night in ICU can cost £6,000 and patients with severe toxicity can spend up to six weeks in ICU; therefore, DPYD testing will have a massive impact on the NHS’ budget.” Cara Thomas, Pre-registration Clinical Scientist, AWMGS
Health Economics impact of adopting DPYD genotyping into your patient pathway
The cost of DPYD genotyping is minimal compared with the financial and health cost burden of prescribing a treatment that will have a chemotoxic reaction, as a result of not performing the simple screening test prior to 5-FU chemotherapy.